Dolutegravir and Genotype drug resistance test positive - a phase IV clinical study of FDA data

Summary:

Genotype drug resistance test positive is reported as a side effect among people who take Dolutegravir (dolutegravir), especially for people who are male, 50-59 old, have been taking the drug for 2 - 5 years also take Ritonavir, and have Hiv infection.

The phase IV clinical study analyzes which people have Genotype drug resistance test positive when taking Dolutegravir. It is created by eHealthMe based on reports of 7,061 people who have side effects when taking Dolutegravir from the FDA, and is updated regularly.

What is Dolutegravir?

Dolutegravir has active ingredients of dolutegravir. eHealthMe is studying from 7,071 Dolutegravir users. Check the latest studies of Dolutegravir.

What is Genotype drug resistance test positive?

Genotype drug resistance test positive is found to be associated with 58 drugs and 64 conditions by eHealthMe. Check the latest studies of Genotype drug resistance test positive.

On Jul, 11, 2026

7,061 people reported to have side effects when taking Dolutegravir.
Among them, 50 people (0.71%) have Genotype drug resistance test positive.

Could Dolutegravir cause Genotype drug resistance test positive?

Among these 50 people:

How long have people been on Dolutegravir when they have Genotype drug resistance test positive? *

What is the gender of people who have Genotype drug resistance test positive when taking Dolutegravir? *

female: 39.02 %
male: 60.98 %

What is the age of people who have Genotype drug resistance test positive when taking Dolutegravir? *

What are other drugs people take besides Dolutegravir? *

What are other side effects people have besides Genotype drug resistance test positive? *

Drug Ineffective: 20 people, 40.00%
Blood Hiv Rna Increased: 16 people, 32.00%
Indigestion: 13 people, 26.00%
Hepatitis B Dna Increased: 13 people, 26.00%
Itching: 13 people, 26.00%
Death: 6 people, 12.00%
Hepatitis B: 5 people, 10.00%
Viral Load Increased: 5 people, 10.00%
Chronic Kidney Disease: 4 people, 8.00%
Weight Increased: 4 people, 8.00%

What are the existing conditions these people have? *

Hiv Infection: 34 people, 68.00%
Hepatitis B: 10 people, 20.00%
Herpes Dermatitis (skin inflammation caused by a herpes simplex virus (hsv)): 3 people, 6.00%
Diabetes: 3 people, 6.00%
Hepatitis C: 2 people, 4.00%
High Blood Pressure: 1 person, 2.00%
Gastritis (inflammation of stomach): 1 person, 2.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 2.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dolutegravir and have Genotype drug resistance test positive?

- Check whether Genotype drug resistance test positive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dolutegravir:

Dolutegravir (7,071 reports)

Genotype drug resistance test positive treatments and more:

Genotype drug resistance test positive (1,107 reports)

How severe was Genotype drug resistance test positive and when was it recovered:

Genotype drug resistance test positive in Dolutegravir

Expand to all the drugs that have ingredients of dolutegravir:

Genotype drug resistance test positive and drugs with ingredients of dolutegravir (50 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dolutegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Genotype drug resistance test positive:

Genotype drug resistance test positive (58 drugs)

Browse all the conditions that are associated with Genotype drug resistance test positive:

Genotype drug resistance test positive (64 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dolutegravir (the active ingredients of Dolutegravir) and Dolutegravir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.